- Report
- May 2024
- 391 Pages
Global
From €5287EUR$6,186USD£4,350GBP
- Report
- June 2023
- 308 Pages
Global
From €4801EUR$5,617USD£3,950GBP
- Report
- July 2022
- 461 Pages
Global
From €4801EUR$5,617USD£3,950GBP
- Report
- May 2024
- 1175 Pages
Global
€1823EUR$2,133USD£1,500GBP
- Report
- September 2023
- 280 Pages
Global
From €4801EUR$5,617USD£3,950GBP
- Report
- December 2022
- 437 Pages
Global
From €4801EUR$5,617USD£3,950GBP
- Report
- June 2025
Global
From €300EUR$363USD£264GBP
- Report
- June 2025
Global
From €300EUR$363USD£264GBP
- Report
- August 2023
- 267 Pages
Global
From €2150EUR$2,603USD£1,895GBP
- Report
- July 2022
- 60 Pages
Global
From €600EUR$726USD£529GBP
- Report
- May 2022
- 50 Pages
Global
From €500EUR$605USD£441GBP
- Report
- October 2021
- 433 Pages
Global
From €2250EUR$2,724USD£1,983GBP
- Report
- July 2021
- 259 Pages
Global
From €2150EUR$2,603USD£1,895GBP
- Report
- November 2022
- 154 Pages
Global
From €4424EUR$5,000USD£3,767GBP
- Report
- December 2019
- 59 Pages
Global
From €3539EUR$4,000USD£3,013GBP
- Report
- May 2024
- 387 Pages
Global
From €4379EUR$4,950USD£3,729GBP
- Report
- December 2023
- 307 Pages
Global
From €4379EUR$4,950USD£3,729GBP
- Report
- May 2024
- 420 Pages
Global
From €2654EUR$3,000USD£2,260GBP
- Report
- December 2023
- 220 Pages
Global
From €2920EUR$3,300USD£2,486GBP
- Report
- October 2023
- 420 Pages
Global
From €2566EUR$2,900USD£2,185GBP

The Monoclonal Antibodies market is a subset of the biotechnology industry that focuses on the production and use of monoclonal antibodies (mAbs). mAbs are laboratory-produced proteins that are designed to bind to specific targets, such as proteins, cells, or tissues. They are used in a variety of applications, including diagnostics, therapeutics, and research.
The market for mAbs is growing rapidly, driven by advances in biotechnology and the increasing demand for personalized medicine. mAbs are used in a variety of treatments, including cancer, autoimmune diseases, and infectious diseases. They are also used in research to develop new treatments and to improve existing treatments.
The market for mAbs is highly competitive, with many companies offering a wide range of products. Major players in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are investing heavily in research and development to develop new mAbs and to improve existing products.
In conclusion, the Monoclonal Antibodies market is an important part of the biotechnology industry, with many companies investing heavily in research and development to develop new products and improve existing treatments. Major players in the market include AbbVie, Amgen, AstraZeneca, Show Less Read more